| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Teresa Pollicino | Q42852280 |
| Massimo Levrero | Q67592879 | ||
| P2093 | author name string | Laura Belloni | |
| Maura Dandri | |||
| Giovanni Raimondo | |||
| Jorg Petersen | |||
| P433 | issue | 3 | |
| P921 | main subject | Hepatitis B virus | Q6844 |
| hepatitis B | Q6853 | ||
| virus | Q808 | ||
| P304 | page(s) | 581-592 | |
| P577 | publication date | 2009-06-10 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Control of cccDNA function in hepatitis B virus infection | |
| P478 | volume | 51 |
| Q59354605 | -methyladenosine modification of hepatitis B virus RNA differentially regulates the viral life cycle |
| Q35778059 | A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide. |
| Q40409379 | A T7 Endonuclease I Assay to Detect Talen-Mediated Targeted Mutation of HBV cccDNA. |
| Q93075340 | A global scientific strategy to cure hepatitis B |
| Q38793556 | A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins |
| Q33585283 | A new model mimicking persistent HBV e antigen-negative infection using covalently closed circular DNA in immunocompetent mice. |
| Q38851736 | A sensitive and accurate quantification method for the detection of hepatitis B virus covalently closed circular DNA by the application of a droplet digital polymerase chain reaction amplification system |
| Q28744484 | A ubiquitin independent degradation pathway utilized by a hepatitis B virus envelope protein to limit antigen presentation |
| Q35168444 | AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication |
| Q38948529 | Activating the innate immune response to counter chronic hepatitis B virus infection |
| Q38770558 | Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus |
| Q37562042 | An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases |
| Q35097694 | Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection |
| Q26782742 | Anti-HBV Drugs: Progress, Unmet Needs, and New Hope |
| Q42177056 | Association between HBV Pre-S mutations and the intracellular HBV DNAs in HBsAg-positive hepatocellular carcinoma in China |
| Q36054401 | Association of Hepatitis B Virus Covalently Closed Circular DNA and Human APOBEC3B in Hepatitis B Virus-Related Hepatocellular Carcinoma |
| Q78177465 | Association of N6-methyladenosine with viruses and related diseases. |
| Q38982082 | Basis of HBV persistence and new treatment options |
| Q40183159 | Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism |
| Q40580426 | CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. |
| Q38618922 | CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV. |
| Q41218683 | Can engineered "designer" T cells outsmart chronic hepatitis B? |
| Q57279174 | Characterization and risk of blood-borne virus transmission in organ transplantation: what are the priorities? |
| Q41816507 | Characterization of nucleosome positioning in hepadnaviral covalently closed circular DNA minichromosomes |
| Q38685587 | Clinical relevance of the study of hepatitis B virus covalently closed circular DNA. |
| Q33695646 | Clinical significance of hepatitis B virion and SVP productivity: relationships between intrahepatic and serum markers in chronic hepatitis B patients |
| Q93064793 | Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection |
| Q35078104 | Combined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure |
| Q34602531 | Comparative analysis of CpG islands among HBV genotypes |
| Q34489239 | Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. |
| Q58580094 | Comprehensive Analysis of Hepatitis B Virus Promoter Region Mutations |
| Q34152074 | Contradictory immune response in post liver transplantation hepatitis B and C. |
| Q38466831 | Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? |
| Q38541052 | Core protein: A pleiotropic keystone in the HBV lifecycle |
| Q40306554 | Cure Strategies for Hepatitis B Virus: The Promise of Immunotherapy |
| Q28084820 | Current and future antiviral drug therapies of hepatitis B chronic infection |
| Q41919714 | Current landscape and future prospects of antiviral drugs derived from microbial products |
| Q37347289 | DDB1 Stimulates Viral Transcription of Hepatitis B Virus via HBx-Independent Mechanisms |
| Q34594010 | DDX3 DEAD-box RNA helicase is a host factor that restricts hepatitis B virus replication at the transcriptional level |
| Q36993940 | Deregulation of epigenetic mechanisms by the hepatitis B virus X protein in hepatocarcinogenesis |
| Q37274697 | Design of therapeutic vaccines: hepatitis B as an example |
| Q32183310 | Detection of HBV Covalently Closed Circular DNA |
| Q41449217 | Development of magnetic capture hybridization and quantitative polymerase chain reaction for hepatitis B virus covalently closed circular DNA. |
| Q34757381 | Diagnostic strategy for occult hepatitis B virus infection |
| Q43279175 | Differential assembly of Hepatitis B Virus core protein on single- and double-stranded nucleic acid suggest the dsDNA-filled core is spring-loaded. |
| Q33677072 | Discovery and Development of Anti-HBV Agents and Their Resistance |
| Q52764230 | Drugs in Development for Hepatitis B. |
| Q42266145 | Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver. |
| Q35682975 | Dynamics of HBV cccDNA expression and transcription in different cell growth phase |
| Q42243264 | Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment |
| Q41553599 | Effects of the Treg/Th17 cell balance and their associated cytokines in patients with hepatitis B infection |
| Q37971052 | Emerging pipeline drugs for hepatitis B infection |
| Q34756805 | Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line |
| Q90416073 | Epigenetic modulation in chronic hepatitis B virus infection |
| Q36860286 | Epigenetically regulated miR-449a enhances hepatitis B virus replication by targeting cAMP-responsive element binding protein 5 and modulating hepatocytes phenotype |
| Q38770516 | Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators |
| Q91670471 | Evans Blue Inhibits HBV Replication Through a Dual Antiviral Mechanism by Targeting Virus Binding and Capsid Assembly |
| Q38035173 | Experimental models and therapeutic approaches for HBV. |
| Q90322976 | Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift |
| Q55496560 | Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus. |
| Q41919479 | Flavocoxid exerts a potent antiviral effect against hepatitis B virus. |
| Q33686965 | Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. |
| Q38415638 | Genetic and epigenetic alterations in hepatitis B virus-associated hepatocellular carcinoma |
| Q26751031 | Genetic variation of occult hepatitis B virus infection |
| Q52590505 | Genome editing for the treatment of tumorigenic viral infections and virus-related carcinomas. |
| Q29048191 | Genome-wide identification of direct HBx genomic targets |
| Q48860247 | Global strategies are required to cure and eliminate HBV infection. |
| Q47570782 | Great and rapid HBsAg decline in patients with on-treatment hepatitis flare in early phase of potent antiviral therapy. |
| Q90682059 | HBV cccDNA and Its Potential as a Therapeutic Target |
| Q37864117 | HBV life cycle and novel drug targets |
| Q40162017 | HBx-elevated MSL2 Modulates HBV cccDNA through Inducing Degradation of APOBEC3B to Enhance Hepatocarcinogenesis. |
| Q41503381 | Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus |
| Q59356515 | Hepatic Failure by Spontaneous Reactivation of Hepatitis B Virus without a Trigger Factor in a Patient with Anti-HBs |
| Q37378812 | Hepatitis B Virus Protein X Induces Degradation of Talin-1. |
| Q97075751 | Hepatitis B Virus RNA Profiles in Liver Biopsies by Digital Polymerase Chain Reaction |
| Q92263429 | Hepatitis B Virus cccDNA in Hepatocellular Carcinoma Tissue Increases the Risk of Recurrence After Liver Transplantation |
| Q26775635 | Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte |
| Q38805093 | Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals |
| Q38025445 | Hepatitis B serological changes following allogeneic bone marrow transplantation |
| Q42252824 | Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study |
| Q34387363 | Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load--down-regulated transcription of PgRNA has limited impact |
| Q36947870 | Hepatitis B viral RNA directly mediates down-regulation of the tumor suppressor microRNA miR-15a/miR-16-1 in hepatocytes |
| Q37773582 | Hepatitis B virology for clinicians |
| Q37776350 | Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): Molecular mechanisms and novel paradigms |
| Q34404975 | Hepatitis B virus and hepatitis C virus dual infection |
| Q58235500 | Hepatitis B virus infection |
| Q35055364 | Hepatitis B virus large surface protein: function and fame. |
| Q37049118 | Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat |
| Q38046619 | Hepatitis B virus: from immunobiology to immunotherapy |
| Q41478058 | Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation |
| Q33899640 | Hepatocarcinogenesis associated with hepatitis B, delta and C viruses |
| Q42977652 | Histone deacetylase inhibition activates transgene expression from integration-defective lentiviral vectors in dividing and non-dividing cells. |
| Q42218316 | Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA. |
| Q40004593 | Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. |
| Q40679075 | IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome |
| Q35845361 | IL6 Inhibits HBV Transcription by Targeting the Epigenetic Control of the Nuclear cccDNA Minichromosome |
| Q90648680 | INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids |
| Q59359129 | Ideal Cure for Hepatitis B Infection: The Target is in Sight |
| Q36122356 | Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA. |
| Q26866955 | Immune responses to HCV and other hepatitis viruses |
| Q40409360 | Immunofluorescent Staining for the Detection of the Hepatitis B Core Antigen in Frozen Liver Sections of Human Liver Chimeric Mice |
| Q36073739 | Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections |
| Q38262108 | Immunopathogenesis of chronic hepatitis B. |
| Q51872199 | Impact of intrahepatic hepatitis B DNA and covalently closed circular DNA on survival after hepatectomy in HBV-associated hepatocellular carcinoma patients. |
| Q40616989 | Impact of non-neoplastic vs intratumoural hepatitis B viral DNA and replication on hepatocellular carcinoma recurrence |
| Q90631727 | In Vitro Systems for Studying Different Genotypes/Sub-Genotypes of Hepatitis B Virus: Strengths and Limitations |
| Q37095706 | In vivo models of hepatitis B and C virus infection. |
| Q95000125 | In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice |
| Q37254885 | Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. |
| Q40847895 | Infection Patterns Induced in Naive Adult Woodchucks by Virions of Woodchuck Hepatitis Virus Collected during either the Acute or Chronic Phase of Infection. |
| Q63246645 | Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx-DDB1 Interaction |
| Q36333991 | Inhibition of duck hepatitis B virus replication by mimic peptides in vitro |
| Q38844134 | Inhibition of hepatitis B virus replication by quercetin in human hepatoma cell lines |
| Q57207207 | Interplay between hepatitis B virus and innate immune signaling pathways |
| Q54373860 | Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. |
| Q34407460 | Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses |
| Q55398183 | Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo. |
| Q42198656 | Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection |
| Q34757408 | Management of occult hepatitis B virus infection: an update for the clinician. |
| Q64115605 | Mapping the Heterogeneity of Histone Modifications on Hepatitis B Virus DNA Using Liver Needle Biopsies Obtained from Chronically Infected Patients |
| Q93079831 | Mapping the Interactions of HBV cccDNA with Host Factors |
| Q38837061 | Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential |
| Q38566445 | Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics |
| Q26781737 | MicroRNAs as Important Players in Host-hepatitis B Virus Interactions |
| Q33661037 | MicroRNAs as therapeutic strategy for hepatitis B virus-associated hepatocellular carcinoma: current status and future prospects |
| Q93140597 | MicroRNA‑20 induces methylation of hepatitis B virus covalently closed circular DNA in human hepatoma cells |
| Q91825014 | Mitochondria ubiquitin ligase, MARCH5 resolves hepatitis B virus X protein aggregates in the liver pathogenesis |
| Q45367082 | Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. |
| Q26799246 | Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence |
| Q33883921 | Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia |
| Q26823512 | Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis |
| Q27002598 | Mouse models of hepatitis B virus infection comprising host-virus immunologic interactions |
| Q36691039 | Mutual antagonism between hepatitis B viral mRNA and host microRNA let-7. |
| Q63246379 | N-Methyladenosine and Viral Infection |
| Q45365306 | Novel poly (ADP-ribose) polymerase 1 binding motif in hepatitis B virus core promoter impairs DNA damage repair |
| Q37418293 | Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. |
| Q27030828 | Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B |
| Q36518847 | Occult HBV infection |
| Q36589567 | Occult hepatitis B demonstrated by anti-HBc and HBV DNA in HIV-positive patients |
| Q33661018 | Occult hepatitis B virus and hepatocellular carcinoma |
| Q38179533 | Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review |
| Q38542377 | Occult hepatitis B virus infection in Egypt |
| Q36514736 | Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy |
| Q42709679 | Occult hepatitis B virus infection: a complex entity with relevant clinical implications |
| Q43223881 | Occult hepatitis B: clinical viewpoint and management. |
| Q40280136 | Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study. |
| Q38295860 | Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy? |
| Q37666948 | Optimizing antiviral agents for hepatitis B management in malignant lymphomas. |
| Q64245215 | Paradoxical Roles of Oxidative Stress Response in the Digestive System before and after Carcinogenesis |
| Q28284012 | Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma |
| Q35628610 | Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis |
| Q47549922 | Peretinoin, an Acyclic Retinoid, Inhibits Hepatitis B Virus Replication by Suppressing Sphingosine Metabolic Pathway In Vitro. |
| Q34289969 | Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. |
| Q42579790 | Persistent human hepatitis B virus infection in cynomolgus monkeys: a novel animal model in the search for a cure? |
| Q90755927 | Pevonedistat, a Neuronal Precursor Cell-Expressed Developmentally Down-Regulated Protein 8-Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus |
| Q59137720 | Post-translational Modification Control of HBV Biological Processes |
| Q26751777 | Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation |
| Q39782358 | Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses |
| Q36951290 | Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus |
| Q104064556 | Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients |
| Q37433006 | Quantification of pregenomic RNA and covalently closed circular DNA in hepatitis B virus-related hepatocellular carcinoma |
| Q40097433 | Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma |
| Q38194061 | Recent insights into hepatitis B virus-host interactions. |
| Q88881196 | Recommendations for the treatment of hepatitis B in 2017 |
| Q34769837 | Regulation of gene expression in HBV- and HCV-related hepatocellular carcinoma: integrated GWRS and GWGS analyses |
| Q38153384 | Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs |
| Q38815666 | Replication of a chronic hepatitis B virus genotype F1b construct. |
| Q39606714 | Replicative activity of hepatitis B virus is negatively associated with methylation of covalently closed circular DNA in advanced hepatitis B virus infection |
| Q38949360 | Requirement of CRTC1 coactivator for hepatitis B virus transcription |
| Q126650972 | Retracted Article: MicroRNA-1271 modulates hepatitis B virus replication, cell proliferation and apoptosis in hepatitis B virus-related hepatocellular carcinoma by targeting SIRT1 |
| Q35772972 | Retracted: Circulating FoxP3+ Regulatory T and Interleukin17-Producing Th17 Cells Actively Influence HBV Clearance in De Novo Hepatitis B Virus Infected Patients after Orthotopic Liver Transplantation |
| Q35237316 | Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. |
| Q28069574 | Roles of hepatocyte nuclear factors in hepatitis B virus infection |
| Q37725585 | SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B. |
| Q33875691 | Sequences in the terminal protein and reverse transcriptase domains of the hepatitis B virus polymerase contribute to RNA binding and encapsidation |
| Q40736922 | Serum hepatitis B surface antigen correlates with tissue covalently closed circular DNA in patients with hepatitis B-associated hepatocellular carcinoma |
| Q38838683 | Sodium selenite suppresses hepatitis B virus transcription and replication in human hepatoma cell lines |
| Q41527993 | Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection |
| Q91710585 | Subversion of cellular autophagy during virus infection: Insights from hepatitis B and hepatitis C viruses |
| Q34992624 | Superinfection with woodchuck hepatitis virus strain WHVNY of livers chronically infected with strain WHV7 |
| Q38543596 | Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. |
| Q38514244 | T-cell responses in hepatitis B and C virus infection: similarities and differences |
| Q28119132 | TGF-β triggers HBV cccDNA degradation through AID-dependent deamination |
| Q38333058 | Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA. |
| Q34459390 | The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo |
| Q26771469 | The Epigenetic Control of Hepatitis B Virus Modulates the Outcome of Infection |
| Q34797681 | The Human Bocavirus Is Associated with Some Lung and Colorectal Cancers and Persists in Solid Tumors |
| Q32182914 | The Role of cccDNA in HBV Maintenance |
| Q42048428 | The Structural Biology of Hepatitis B Virus: Form and Function |
| Q35248001 | The Tudor domain protein Spindlin1 is involved in intrinsic antiviral defense against incoming hepatitis B Virus and herpes simplex virus type 1 |
| Q42406515 | The clinical significance of occult HBV infection |
| Q28485228 | The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes |
| Q34473782 | The hepatitis B virus x protein inhibits thymine DNA glycosylase initiated base excision repair |
| Q41610650 | The interface between hepatitis B virus capsid proteins affects self-assembly, pregenomic RNA packaging, and reverse transcription |
| Q36898145 | The recombined cccDNA produced using minicircle technology mimicked HBV genome in structure and function closely |
| Q45324582 | Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome |
| Q45000753 | Treatment of human immunodeficiency virus and hepatitis B virus infections |
| Q57464753 | Tridimensional infiltration of DNA viruses into the host genome shows preferential contact with active chromatin |
| Q37800793 | Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets |
| Q59353290 | Understanding the hepatitis B core positive liver donor |
| Q26781990 | Update on Hepatitis B Virus Infection: Focus on Treatment |
| Q34733579 | Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA. |
| Q27013917 | Viral quasispecies evolution |
| Q40850304 | Virology: The X-Files of hepatitis B. |
| Q33723810 | Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma |
| Q39272853 | Virus-host interplay in hepatitis B virus infection and epigenetic treatment strategies |
| Q56940144 | When Hepatitis B Virus Meets Interferons |
| Q39175156 | c-Myc-mediated overexpression of miR-17-92 suppresses replication of hepatitis B virus in human hepatoma cells |
| Q40873221 | microRNAs and Hepatitis B. |
| Q40769626 | α-Fetoprotein level-dependent early hepatitis B surface antigen decline during entecavir therapy in chronic hepatitis B with hepatitis flare |
Search more.